In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter
Neurourology and Urodynamics · 2024
DOI: 10.1002/nau.25483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurourology and Urodynamics, 2024. Verfasst von Meylis Artykov und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hacettepe University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Acetanilides, Thiazoles, Ureter, Adrenergic beta-3 Receptor Agonists. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Hacettepe Üniversitesi.
Abstract (Originalsprache)
Introduction
This study aimed to investigate the effect of mirabegron, a β3‐adrenoceptor agonist with widespread clinical use for treating overactive bladder disease, on isolated healthy human ureter strips. Materials and Methods This was a prospective study employing a series of in vitro organ bath experiments using ureteral tissues of kidney grafts from 10 healthy donors. The ureteral strips were subjected to cumulative mirabegron concentrations (10 −9 –10 −4.5 M). Effects on frequency or amplitude of spontaneous, 10 mM KCl‐ or EFS‐induced contractions were evaluated.
Results
Mirabegron decreased the frequency of spontaneous ureteric contraction in a concentration‐dependent manner. Statistically significant decrease in the frequency of spontaneous contraction was observed at 10 −8 –10 −4.5 M. In 10 mM KCl medium, statistically significant change in frequency was observed at 10 −9 –10 −4.5 M. Statistically significant decrease in the amplitudes of spontaneous contraction was observed at 10 −7 –10 −4.5 M. In a 10 mM KCl medium, statistically significant change in amplitudes was observed at 10 −8 –10 −4.5 M.
Conclusions
Mirabegron reduced the amplitude and frequency of human ureter activity in in vitro organ bath studies. This effect was achieved in a dose‐dependent manner on isolated tissue strips. Although monotherapy with mirabegron remains uncertain, this study has the potential to elucidate the mechanism underlying the effectiveness of mirabegron, particularly in combination therapy for ureteral stones.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Department of Pharmacology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Förderung
- Hacettepe Üniversitesi
Zitieren
APA
Artykov, M., Ozcelebi, E., Sara, M. Y., Gudeloglu, A., Iskit, A. B., & Aki, F. T. (2024). In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25483
Vancouver
Artykov M, Ozcelebi E, Sara MY, Gudeloglu A, Iskit AB, Aki FT. In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter. Neurourology and Urodynamics. 2024. doi:10.1002/nau.25483
BibTeX
@article{Artykov2024,
author = {Artykov, Meylis and Ozcelebi, Esin and Sara, Mehmet Yildirim and Gudeloglu, Ahmet and Iskit, Alper Bektas and Aki, Fazil Tuncay},
title = {In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter},
journal = {Neurourology and Urodynamics},
year = {2024},
doi = {10.1002/nau.25483}
}
EUVIMED